| Revenue growth | 5.6% YoY for Q4FY26; 6.1% for full year FY26. |
|---|---|
| Margins | EBITDA margin at 20.3% in Q4FY26 vs 21.4% in Q4FY25. |
| Demand visibility | Strong Europe performance; stable US base business despite seasonality. |
Growth
FY26 revenue grew 6.1% YoY to ₹33,653 Cr; Europe grew 23.4% and Growth Markets 10% in FY26.
Outlook
Targets 7-8 marketed biosimilars in EU/UK/Canada by 2030; USD 150-175 Mn CAPEX for TheraNym Unit 2.
Risks
USA revenue declined 13% YoY in Q4 due to seasonality and lower transient product sales.
Earnings Call filed with NSE, NSE: AUROPHARMA. Summary written with AI assistance from the document.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,682.00
- Market cap
- ₹97,691 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 24.8×Sector 47.3×
- Promoter holding
- 51.88%+0.06% QoQ
- FII holding
- 16.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Regulatory Approval
Aurobindo Pharma received USFDA final approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol. The US market for this segment is estimated at US$301 million.
Aurobindo Pharma Acquisition Worth ₹9.47 Cr
Aurobindo Pharma's subsidiary acquired A1 Biochem USA Inc for ₹9.47 Crore. This 100% acquisition expands its contract research and development services capabilities in the USA.
- Value
- ₹9.47 Cr
Aurobindo Pharma Merger & Restructuring Worth ₹9.5 Cr
Aurobindo Pharma's subsidiary, A1 Biochem Labs (India), invested USD 1,000,000 (approx. ₹9.5 Crore) to incorporate and capitalize a new US subsidiary, A1 Biochem USA Inc.
- Value
- ₹9.50 Cr
Aurobindo Pharma Business Update
Aurobindo Pharma announced that the US FDA inspection of its subsidiary Apitoria Pharma's Unit-IV concluded with zero observations. This signals continued regulatory compliance for the facility.
Aurobindo Pharma Merger & Restructuring Worth ₹5 Cr
Aurobindo Pharma's subsidiary, Apitoria Pharma, incorporated a new wholly owned subsidiary named Avogent Lifesciences. The initial capital subscription for this pharmaceutical entity is Rs. 5 Crore.
- Value
- ₹5.00 Cr
Aurobindo Pharma Product Launch
Aurobindo Pharma's subsidiary, Lannett Company LLC, launched the generic version of Advair Diskus® in the US. This marks the company's first commercialized product from its inhalation pipeline.